Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Horizon Therapeutics Public Limited Company - Ordinary Shares (NQ: HZNP )

N/A UNCHANGED
Last Price Updated: 4:00 PM EDT, Oct 5, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Horizon Therapeutics Public Limited Company - Ordinary Shares

< Previous 1 2
...
5 6 7 8 9 10 11 12 13
...
16 17 Next >
12 Health Care Stocks Moving In Wednesday's Intraday Session
Via Benzinga
Crude Oil Rises Sharply; XPeng Shares Spike Higher
U.S. stocks traded mixed midway through trading, with the Nasdaq Composite gaining around 25 points on Wednesday. 
Via Benzinga
Arcimoto (FUV) Stock Falls After 1-for-20 Reverse Split
Arcimoto (FUV) stock isn't doing so hot as the EV company's shares are falling following a one-for-20 reverse stock split. 
Via InvestorPlace
Why Are Chinese EV Stocks XPEV, LI, NIO Up Today?
Chinese EV stocks are climbing higher on Wednesday and they have Xpeng (XPEV) earnings to thank for the positive movement. 
Via InvestorPlace
Workday, XPeng, Titan Machinery And Some Other Big Stocks Moving Higher On Wednesday
U.S. stocks traded lower, with the Dow Jones dropping over 200 points on Wednesday. Here are some big stocks recording gains in today’s session. 
Via Benzinga
$100 Invested In Horizon Therapeutics 10 Years Ago Would Be Worth This Much Today
Via Benzinga
Why Horizon Therapeutics' Shares Rose 11.32% on Wednesday
The company released encouraging year-end guidance. 
Via The Motley Fool
Why Horizon Therapeutics Stock Is Skyrocketing Today
Three big drugmakers could be interested in acquiring Horizon. 
Via The Motley Fool
Why Is Horizon Therapeutics (HZNP) Stock Up 30% Today?
Horizon Therapeutics (HZNP) stock is rising higher on Wednesday following reports that the company is considering a buyout. 
Via InvestorPlace
US Stocks Mixed; Dow Drops 200 Points
U.S. stocks traded mixed this morning, with the Dow Jones dropping around 200 points on Wednesday. 
Via Benzinga
This Is What Whales Are Betting On Horizon Therapeutics
Someone with a lot of money to spend has taken a bearish stance on Horizon Therapeutics (NASDAQ:HZNP). And retail traders should know. We noticed this today when the big position showed up on publicly... 
Via Benzinga
iPhone Pro Shipments May Miss Consensus, Tesla Rival Charts Ambitious Expansion Plan In Mexico, Amazon Cloud Unit To Add More Employees: Top Stories Wednesday, Nov. 30
Reuters 
Via Benzinga
Recap: Horizon Therapeutics Q3 Earnings
Horizon Therapeutics (NASDAQ:HZNP) reported its Q3 earnings results on Wednesday, November 2, 2022 at 07:00 AM. Here's what investors need to know about the announcement. 
Via Benzinga
Horizon Therapeutics Shares Jump On Confirmation Of Takeover Talks With Several Large Companies
Via Benzinga
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Via Benzinga
Why Horizon Therapeutics Shares Are Trading Higher By Over 30%; Here Are 32 Stocks Moving Premarket
Gainers Kalera Public Limited Company (NASDAQ: KAL) shares rose 33.3% to $0.2399 in pre-market trading after jumping 45% on Tuesday. Kalera recently announced restructuring process for German... 
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday
We're starting off the day with a breakdown of the biggest pre-market stock movers traders need to know about for Wednesday! 
Via InvestorPlace
Horizon Therapeutics Rockets As It Considers Potential Bids From Amgen, J&J, Sanofi
The three companies have until Jan. 10 to decide whether they want to buy Horizon. 
Via Investor's Business Daily
Horizon Therapeutics plc Confirms Preliminary Discussions Regarding Potential Offer
From Horizon Therapeutics plc
Via Business Wire
Horizon Therapeutics plc Announces Completion of Enrollment of Phase 3 Clinical Trial (OPTIC-J) in Japan Evaluating TEPEZZA® (teprotumumab-trbw) for the Treatment of Active Thyroid Eye Disease (TED)
From Horizon Therapeutics plc
Via Business Wire
Horizon Therapeutics plc Announces Scientific Collaboration with Leading Research Institution to Advance Research in Autoimmunity and Inflammation
From Horizon Therapeutics plc
Via Business Wire
Horizon Therapeutics plc to Participate in Upcoming Investor Healthcare Conferences in November
From Horizon Therapeutics plc
Via Business Wire
Sustained Patient Response to KRYSTEXXA® (pegloticase) Injection with Methotrexate Compared to KRYSTEXXA Alone Shown through Month 12 in MIRROR Randomized Controlled Trial
From Horizon Therapeutics plc
Via Business Wire
Data Support the Use of KRYSTEXXA® (pegloticase) Injection with Methotrexate to Treat Uncontrolled Gout in People With Mild-to-Moderate Chronic Kidney Disease
From Horizon Therapeutics plc
Via Business Wire
United Therapeutics, Super Micro Computer, Novo Nordisk And Other Big Gainers From Wednesday
U.S. stocks closed lower on Wednesday, with the Dow Jones dropping more than 500 points. Here is the list of some big stocks recording gains in the previous session. 
Via Benzinga
Horizon Therapeutics plc Reports Third-Quarter 2022 Financial Results; Increases Full-Year 2022 Net Sales and Adjusted EBITDA Guidance; Increases TEPEZZA and KRYSTEXXA Peak Annual Net Sales Expectations
From Horizon Therapeutics plc
Via Business Wire
Horizon Therapeutics Does Not Have Meaningful Upside, Analyst Initiating Coverage Says
Via Benzinga
Horizon Therapeutics plc Named to the Seramount Inclusion Index
From Horizon Therapeutics plc
Via Business Wire
Benzinga's Top Ratings Upgrades, Downgrades For November 1, 2022
Upgrades 
Via Benzinga
Q32 Bio and Horizon Therapeutics plc Announce Dosing of First Patient in Phase 2 Trial of ADX-914 for Atopic Dermatitis
From Horizon Therapeutics plc and Q32 Bio
Via Business Wire
< Previous 1 2
...
5 6 7 8 9 10 11 12 13
...
16 17 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.